Novel Prostate Cancer Biomarkers: Aetiology, Clinical Performance and Sensing Applications

The review initially provides a short introduction to prostate cancer (PCa) incidence, mortality, and diagnostics. Next, the need for novel biomarkers for PCa diagnostics is briefly discussed. The core of the review provides details about PCa aetiology, alternative biomarkers available for PCa diagnostics besides prostate specific antigen and their biosensing. In particular, low molecular mass biomolecules (ions and metabolites) and high molecular mass biomolecules (proteins, RNA, DNA, glycoproteins, enzymes) are discussed, along with clinical performance parameters.

Automated summary

The review gives an overview of prostate cancer (PCa) incidence, mortality, and diagnostic methods, highlighting the need for novel biomarkers. In addition to prostate specific antigen, the review discusses alternative biomarkers available for PCa diagnostics, including low and high molecular mass biomolecules.